{"name":"Children's Cancer Group, China","slug":"children-s-cancer-group-china","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Course A2 + Vin","genericName":"Course A2 + Vin","slug":"course-a2-vin","indication":"Pediatric acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Course A3 + Vin","genericName":"Course A3 + Vin","slug":"course-a3-vin","indication":"Pediatric cancers (specific indication not clearly defined in available data)","status":"phase_3"},{"name":"Course B3 +Vin","genericName":"Course B3 +Vin","slug":"course-b3-vin","indication":"Pediatric acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Brentuximab Vedotin for Injection","genericName":"Brentuximab Vedotin for Injection","slug":"brentuximab-vedotin-for-injection","indication":"Hodgkin lymphoma","status":"phase_2"},{"name":"Course A1 + Vin","genericName":"Course A1 + Vin","slug":"course-a1-vin","indication":"Pediatric acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Course B1 +Vin","genericName":"Course B1 +Vin","slug":"course-b1-vin","indication":"Pediatric acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","genericName":"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","slug":"cyclophosphamide-vindelsine-cytarabine-doxorubincin-prednisone","indication":"Acute lymphoblastic leukemia, Acute myeloid leukemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Multiple sclerosis","status":"phase_2"},{"name":"Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase","genericName":"Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase","slug":"dexamethasone-cytarabine-etoposide-pegylated-asparaginase","indication":"Acute lymphoblastic leukemia (ALL) in pediatric patients","status":"phase_3"},{"name":"Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone","genericName":"Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone","slug":"ifosphamide-etoposide-methotrexate-vindelsine-prednisone","indication":"Acute lymphoblastic leukemia","status":"phase_2"},{"name":"Methotrexate, 6-mercaptopurine","genericName":"Methotrexate, 6-mercaptopurine","slug":"methotrexate-6-mercaptopurine","indication":"Acute lymphoblastic leukemia (ALL) in pediatric patients","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Bedamustine","genericName":"Bedamustine","slug":"bedamustine","indication":"Other","status":"phase_2"},{"name":"Course B2 +Vin","genericName":"Course B2 +Vin","slug":"course-b2-vin","indication":"Pediatric malignancies (specific indication not publicly detailed)","status":"phase_3"}]}],"pipeline":[{"name":"Course A2 + Vin","genericName":"Course A2 + Vin","slug":"course-a2-vin","phase":"phase_3","mechanism":"Course A2 + Vin is a combination chemotherapy regimen that uses doxorubicin and vincristine to inhibit cancer cell division and induce apoptosis in pediatric malignancies.","indications":["Pediatric acute lymphoblastic leukemia (ALL)","Pediatric lymphomas"],"catalyst":""},{"name":"Course A3 + Vin","genericName":"Course A3 + Vin","slug":"course-a3-vin","phase":"phase_3","mechanism":"Course A3 + Vin is a combination chemotherapy regimen combining doxorubicin, cyclophosphamide, and vincristine used to treat pediatric cancers.","indications":["Pediatric cancers (specific indication not clearly defined in available data)"],"catalyst":""},{"name":"Course B3 +Vin","genericName":"Course B3 +Vin","slug":"course-b3-vin","phase":"phase_3","mechanism":"Course B3 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents to disrupt cancer cell division and induce apoptosis in pediatric malignancies.","indications":["Pediatric acute lymphoblastic leukemia (ALL)","Pediatric lymphomas and other hematologic malignancies"],"catalyst":""},{"name":"Bedamustine","genericName":"Bedamustine","slug":"bedamustine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brentuximab Vedotin for Injection","genericName":"Brentuximab Vedotin for Injection","slug":"brentuximab-vedotin-for-injection","phase":"phase_2","mechanism":"Brentuximab vedotin targets CD30, a protein found on the surface of certain cancer cells, and delivers a toxic agent to these cells.","indications":["Hodgkin lymphoma","Systemic anaplastic large cell lymphoma"],"catalyst":""},{"name":"Course A1 + Vin","genericName":"Course A1 + Vin","slug":"course-a1-vin","phase":"phase_3","mechanism":"Course A1 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents in Course A1 to disrupt microtubule formation and induce apoptosis in cancer cells.","indications":["Pediatric acute lymphoblastic leukemia (ALL)","Pediatric acute myeloid leukemia (AML)"],"catalyst":""},{"name":"Course B1 +Vin","genericName":"Course B1 +Vin","slug":"course-b1-vin","phase":"phase_3","mechanism":"Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells.","indications":["Pediatric acute lymphoblastic leukemia (ALL)","Pediatric lymphomas and other hematologic malignancies"],"catalyst":""},{"name":"Course B2 +Vin","genericName":"Course B2 +Vin","slug":"course-b2-vin","phase":"phase_3","mechanism":"Course B2 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents to inhibit microtubule formation and induce apoptosis in cancer cells.","indications":["Pediatric malignancies (specific indication not publicly detailed)"],"catalyst":""},{"name":"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","genericName":"Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone","slug":"cyclophosphamide-vindelsine-cytarabine-doxorubincin-prednisone","phase":"phase_2","mechanism":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, Vindelsine is a topoisomerase inhibitor that disrupts DNA replication, Cytarabine is a nucleoside analog that inhibits DNA synthesis, Doxorubicin is an anthracycline antibiotic that intercalates DNA, Prednisone is a corticosteroid that suppresses inflammation and immune response.","indications":["Acute lymphoblastic leukemia, Acute myeloid leukemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Multiple sclerosis"],"catalyst":""},{"name":"Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase","genericName":"Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase","slug":"dexamethasone-cytarabine-etoposide-pegylated-asparaginase","phase":"phase_3","mechanism":"This combination regimen uses a corticosteroid, cytotoxic chemotherapy agents, and an amino acid-depleting enzyme to induce apoptosis and inhibit protein synthesis in leukemic cells.","indications":["Acute lymphoblastic leukemia (ALL) in pediatric patients","Acute myeloid leukemia (AML) in pediatric patients"],"catalyst":""},{"name":"Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone","genericName":"Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone","slug":"ifosphamide-etoposide-methotrexate-vindelsine-prednisone","phase":"phase_2","mechanism":"Topoisomerase inhibitor","indications":["Acute lymphoblastic leukemia","Breast cancer","Lymphoma","Ovarian cancer","Testicular cancer"],"catalyst":""},{"name":"Methotrexate, 6-mercaptopurine","genericName":"Methotrexate, 6-mercaptopurine","slug":"methotrexate-6-mercaptopurine","phase":"phase_3","mechanism":"This combination of methotrexate and 6-mercaptopurine inhibits nucleotide synthesis and DNA replication to suppress cancer cell proliferation.","indications":["Acute lymphoblastic leukemia (ALL) in pediatric patients","Acute myeloid leukemia (AML) in pediatric patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1HR2pJQXJsR0JMdGpBX2JINnZaLTk0S3JUd1dsWDVWTVp1WlpDSUs5ZFlzNC03ZTQySzJ4cTZOelRQM2JqUHJiUkxac3llMUE0Tlo0Mlk2ZmZqeXRVSEJ4aUg0TVlYRUFmT2pNVUhsVFQ3MURPelB0amtNNnZBUQ?oc=5","date":"2026-04-08","type":"regulatory","source":"Fierce Pharma","summary":"Regulatory tracker: GSK's Exdensur widens reach with new nod in China - Fierce Pharma","headline":"Regulatory tracker: GSK's Exdensur widens reach with new nod in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNbEc3WEQxM0V0blc4Y1NOb04wY2E1dDRvWldjd1lrNlZUdmJLcGtGUFJaNTdrRjBFWEZLMFBYNHdDNkRDVk1Ma0ctRGVqS1B6TDR2TVo3TzhFSHFvdGJ1bVhEem94UFdzdVNWbUhoM3hqSjRsTjM5dTFZVXpEaDVlX1NWTTVlZ2Z4aFk2aHB1T1ZjWFFpNDN6WFp2WldjUi15eERGdlRHWEU1T1p1SVgzME1IRWY2MlNTTnY2RlJwOEYyemY2d1FsWjdORUhFV1lDY0ZKZVYwZDhNYjdBT0lmb3VJTmRlZ1pLbTczVXVuUERtZk84dWRr?oc=5","date":"2026-02-06","type":"trial","source":"BioPharma APAC","summary":"Australian World First Paediatric mRNA Brain Cancer Trial Signals Expansion Opportunity For Canada And The United States - BioPharma APAC","headline":"Australian World First Paediatric mRNA Brain Cancer Trial Signals Expansion Opportunity For Canada And The United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKQjVRa3Fjay05WEdjelFUYkNVdVQ5VFFPYk42eGRvLXpTOVJYdHJaTjY4RjE3VHlmOWM0SDV1QmZKNEJXTmg0YVd2eEptbllhaklWQy1vRWdwNC1aUmptb1BfdGZLUQ?oc=5","date":"2026-01-05","type":"regulatory","source":"Fierce Pharma","summary":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products - Fierce Pharma","headline":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOeGg4UFBoWDhoMTl0Q0M0Nl9jcnNYWkFHRzRHTVNkejllU0tvMlI0eVh3WFQ1SG5EdmVjU2M5bWx1d3FCckdDUFptd3dxN0hpTFlpS1Z2MHpBT25nNzhZbjcxdG9COG5OWGxLWGRob2FyUUtBNmpQbXFxaGlBcm9vd21oby1ob0F6N29LZFlkNVA4MzJtbXpjcFE5aF9TdU1wWlpKZUFZT1lnVTZvTEJGVU5nOTdUajd4ajRXTTV2VGVzdzA?oc=5","date":"2026-01-02","type":"trial","source":"Fierce Pharma","summary":"Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts phase 3 win - Fierce Pharma","headline":"Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts phase 3 win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMjk1TThWTUYxWEh6amkwZTFDcXdwOGNic2tlT3BGY0RqOHRLdENuZ0VPOHo0WjFfMXRTa2hXbjFrNXVFUUNHSzktUEdZaVlLYUdrLWhydlFaZVZPM1kxXzJDUC1iMkpTUTJWUFhLcEN1Z2pjenJQS2N4S1ZnRnM1ZUtqQkxKRDhpNmpIYVo3c0dnU1ZGQmN4bEFsS0pYalRMMVRYbE5TaEhjcFJJQWVRLWJxMXZiNUpaLWhFZWFrMlZtWW9TMWcwOVBDLWFCX0FYaFpOcGZ5WjhzY2ZDOTJRTVl3MEZORlRh?oc=5","date":"2025-11-10","type":"regulatory","source":"scanx.trade","summary":"Glenmark Pharma Secures Regulatory Approval in China for RYALTRIS®, Expanding Global Reach - scanx.trade","headline":"Glenmark Pharma Secures Regulatory Approval in China for RYALTRIS®, Expanding Global Reach","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOVXJkX1pQaFpRdjdCR29vdS0wb3ZERDczVXo4Z0JFaDBrU3FET0NMUzlTQ08tVURIRk54Uk9KLUxwcnZiMVlSRmZsR1dYTi01V2IxUzJUcHo5WWdwOXZUMW1zTmZ1SW9SeXU2MlotRTRHcXViVlpoR0M5dExNeloxWlh5MmxGMnNQSlUzeXRPWmZBZVgxdjdVR3dmWEE5QnEwWXZSOVpUNnB2SmNzZkhNODk5RG9WZFRXWE5fbTNZQm5BV25DZk95WDBlUm9Ea1FhemVoRHRfNW1vbElZcEE?oc=5","date":"2025-10-17","type":"deal","source":"Reuters","summary":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche - Reuters","headline":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNd2JVck9iNmFCSWdxT2hrdmxUbzdBRURCVzJsOEVBdzhYbFVKWGJjcDJ6VS0yNDRiaWhQT0l4QmdDaE5UUjVYLU95bmdZaTNSSHd4Szd3WjVhQ01vMVFGR09NbkVHMG5XLUVIbDdhRThteUhhbDZfbExhaEQzdlZYUEhkbWxia0U?oc=5","date":"2025-07-14","type":"regulatory","source":"Yahoo Finance","summary":"Ascentage Pharma’s Novel Cancer Drug Approved in China - Yahoo Finance","headline":"Ascentage Pharma’s Novel Cancer Drug Approved in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQdGpYRkI0b1BRdmI5UmNrcTFnaE5zWS14N3dlbW96RTlaZThOOTNrSzRlRDY1M2ZwZkw4WnpndjJfTXhNaDltSDQyX0FKYnJHdl9BQ1E1dlFjcWViSFhJS05Vdk9lZDhVTExldktHVmFqdUpVWXdwYy1OVjZiRHZNOUx2S2l3aEpvWmfSAY8BQVVfeXFMTWFTdXExTS1JQnRkUUZKcFNpVGxiRXpoMHRiZlVMbm8zNGtWcnJUWHhiWm1pYnp5aDl2NG5ld0ZEak5WVzdhOGNnODJwbEhRdlJ4eXN4ejI0QTAtSzZTY3ZVbkgyckNjcmFIYVhlbFJwSG5MNHQ3YVZjVk1GclUxR2ppZWcyaXFnaUN5djVNZUk?oc=5","date":"2025-04-23","type":"pipeline","source":"Al Jazeera","summary":"Trade war with China to hit US healthcare - Al Jazeera","headline":"Trade war with China to hit US healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOYUxyeWxadWwxRzV0OU92aDQ5enlvRHVHMnJxYTM1QmhRY1F3TkZyWWs4cUw1UmJnaTdUeWlhYURiNUh4WmJnS21ZNml3RUtrczNjNWtzRU1MaWswOHVfblhpSW1aQXR3MHVadlVqN1l2UlJOUXE3M0dnb2I1VFNXRVNCTjRHYzVV0gGOAUFVX3lxTE1yZGtmV245TlVFWHloMVpOOExMMHZDc3ZYYm85SVpVV0VnMzE4MmFGMVdQU1RpUDJjTDRUaHZaaVB1UnQxQUsteUE3dVp1TGY3dUhHRjFvQzI3ejZZSEVwNlNrME93c1FhS0l5RzkzUHV3Tm0wMlhwbXc0TjI2UjZCN0Z1ZnFGeVFaYmZuRVE?oc=5","date":"2025-02-13","type":"pipeline","source":"CNBC","summary":"U.S. investors, Big Pharma race to find new medicines in China - CNBC","headline":"U.S. investors, Big Pharma race to find new medicines in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQzdxM1BFQ2RDaGZmaks3YkZtNC1rNklNdW40cGJUeEgyU0JuR1NSUEtiRGJWVjkxVUx4bkpIbWt5WFJONkRiemFDSFBSX0VkSTVXR3pXNl91bEhUUms1bEMyUFBmbmU3VmRnZ1JkVEhLZnd3VFprTkl5N0RNR3cyUzBScEdYbEVPTEE5VVcxYm5saXA2cmx2cmpuRERWTURZWHNFVFp6T3dkWnhyUXN2YWFmeVM1ZFdRdGNaUEIyVQ?oc=5","date":"2025-02-04","type":"pipeline","source":"Sanofi","summary":"Childhood Cancer R&D Program: Developing and Accelerating Novel Therapies for Children With Cancer - Sanofi","headline":"Childhood Cancer R&D Program: Developing and Accelerating Novel Therapies for Children With Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZTZPV3h2X2Y1MG9VM0JQWTF5SG8zLUV4UTBiam1JYUk4RTNSUXN3c2tDNWJLcHNxYzFOSm91cFVVMElJbnFWWlh0dl9qcy1DSUVzNXhkMGFfbURocWFGbW5RLUVnaEJ2b0p5Z2o1a2FIV1h6eWdLaHhjN1RJaXRjWVRuV0c5ZVA5NFFFX3AyVXNGVU9GN3Z6QnZYLTQ2TjF0ZG9CU1ZxdkI4UmM?oc=5","date":"2023-08-09","type":"pipeline","source":"Labiotech.eu","summary":"Meet the startup working to help treat a rare pediatric cancer - Labiotech.eu","headline":"Meet the startup working to help treat a rare pediatric cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOY2ZuQXZOdkk2M1lYRk4tYVg4M1dNY3dwMXBVOGtVdmRPT1RjWk1hdjRzUklfVmllajNGS0lhRVZzeTdXREtfWUQwdV9PMmJlQkNUR0ZmdEhyWHQxdnhrcU9Qa3o2aDlkTWY3dERzTW44VE9LYnBUdkxxWUd6M2hfOWtQZDRRRFlic0V0cllISzZuR0lOUVFyS3lwY2xBVHVnOXBBWFpNaGRvM0dOYXZLWENyTVFDQ29nNC1mWA?oc=5","date":"2023-01-25","type":"pipeline","source":"TBIJ","summary":"The drug was meant to save children’s lives. Instead, they’re dying. - TBIJ","headline":"The drug was meant to save children’s lives. Instead, they’re dying.","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":8,"phase_2":4},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}